Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.

Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I; Memantine Study Group.

JAMA. 2004 Jan 21;291(3):317-24.

PMID:
14734594
2.

Donepezil for vascular cognitive impairment.

Malouf R, Birks J.

Cochrane Database Syst Rev. 2004;(1):CD004395. Review.

PMID:
14974068
3.

The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.

Bond M, Rogers G, Peters J, Anderson R, Hoyle M, Miners A, Moxham T, Davis S, Thokala P, Wailoo A, Jeffreys M, Hyde C.

Health Technol Assess. 2012;16(21):1-470. doi: 10.3310/hta16210. Review.

4.

Lack of evidence for the efficacy of memantine in mild Alzheimer disease.

Schneider LS, Dagerman KS, Higgins JP, McShane R.

Arch Neurol. 2011 Aug;68(8):991-8. doi: 10.1001/archneurol.2011.69. Epub 2011 Apr 11. Review.

PMID:
21482915
5.

Donepezil for dementia due to Alzheimer's disease.

Birks J, Harvey RJ.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD001190. Review.

PMID:
16437430
6.

Memantine for dementia.

Areosa SA, Sherriff F.

Cochrane Database Syst Rev. 2003;(3):CD003154. Review. Update in: Cochrane Database Syst Rev. 2004;(4):CD003154.

PMID:
12917950
7.

Cholinesterase inhibitors for Alzheimer's disease.

Birks J.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005593. Review.

PMID:
16437532
8.

Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer's disease.

Gauthier S, Molinuevo JL.

Alzheimers Dement. 2013 May;9(3):326-31. doi: 10.1016/j.jalz.2011.11.005. Epub 2012 Oct 27. Review.

PMID:
23110864
9.

Galantamine for Alzheimer's disease.

Olin J, Schneider L.

Cochrane Database Syst Rev. 2001;(4):CD001747. Review. Update in: Cochrane Database Syst Rev. 2002;(3):CD001747.

PMID:
11687119
10.

Efficacy and safety of memantine in moderate-to-severe Alzheimer disease: the evidence to date.

Bullock R.

Alzheimer Dis Assoc Disord. 2006 Jan-Mar;20(1):23-9. Review.

PMID:
16493232
11.

Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.

Tan CC, Yu JT, Wang HF, Tan MS, Meng XF, Wang C, Jiang T, Zhu XC, Tan L.

J Alzheimers Dis. 2014;41(2):615-31. doi: 10.3233/JAD-132690. Review.

PMID:
24662102
12.

Galantamine for Alzheimer's disease.

Olin J, Schneider L.

Cochrane Database Syst Rev. 2002;(3):CD001747. Review. Update in: Cochrane Database Syst Rev. 2004;(4):CD001747.

PMID:
12137632
13.

Donepezil for dementia due to Alzheimer's disease.

Birks JS, Harvey R.

Cochrane Database Syst Rev. 2003;(3):CD001190. Review. Update in: Cochrane Database Syst Rev. 2006;(1):CD001190.

PMID:
12917900
14.

A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease.

Di Santo SG, Prinelli F, Adorni F, Caltagirone C, Musicco M.

J Alzheimers Dis. 2013;35(2):349-61. doi: 10.3233/JAD-122140. Review.

PMID:
23411693
15.

Perspectives in the management of Alzheimer's disease: clinical profile of donepezil.

Rogers SL.

Dement Geriatr Cogn Disord. 1998;9 Suppl 3:29-42. Review.

PMID:
9853200
16.

Time to Treatment Initiation in People With Alzheimer Disease: A Meta-Analysis of Randomized Controlled Trials.

Tsoi KK, Hirai HW, Chan JY, Kwok TC.

J Am Med Dir Assoc. 2016 Jan;17(1):24-30. doi: 10.1016/j.jamda.2015.08.007. Epub 2015 Sep 26. Review.

PMID:
26392193
17.

Treatment of Alzheimer's disease in the long-term-care setting.

Smith DA.

Am J Health Syst Pharm. 2009 May 15;66(10):899-907. doi: 10.2146/ajhp070622. Review.

PMID:
19420308
18.

A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer's disease.

Deardorff WJ, Grossberg GT.

Drug Des Devel Ther. 2016 Oct 3;10:3267-3279. eCollection 2016. Review.

19.

Refining treatment guidelines in Alzheimer's disease.

Doody RS.

Geriatrics. 2005 Jun;Suppl:14-20. Review.

PMID:
16025771
20.

Latrepirdine for Alzheimer's disease.

Chau S, Herrmann N, Ruthirakuhan MT, Chen JJ, Lanctôt KL.

Cochrane Database Syst Rev. 2015 Apr 21;(4):CD009524. doi: 10.1002/14651858.CD009524.pub2. Review.

PMID:
25897825

Supplemental Content

Support Center